MX2020007665A - Terapia de combinacion para tratar o prevenir el cancer. - Google Patents
Terapia de combinacion para tratar o prevenir el cancer.Info
- Publication number
- MX2020007665A MX2020007665A MX2020007665A MX2020007665A MX2020007665A MX 2020007665 A MX2020007665 A MX 2020007665A MX 2020007665 A MX2020007665 A MX 2020007665A MX 2020007665 A MX2020007665 A MX 2020007665A MX 2020007665 A MX2020007665 A MX 2020007665A
- Authority
- MX
- Mexico
- Prior art keywords
- treating
- combination therapy
- preventing cancer
- cancer
- preventing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invención provee una terapia de combinación que comprende una cepa bacteriana para el tratamiento y la prevención del cáncer.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1800927.4A GB201800927D0 (en) | 2018-01-19 | 2018-01-19 | Combination therapy for treating or preventing cancer |
GBGB1801502.4A GB201801502D0 (en) | 2018-01-30 | 2018-01-30 | Combination therapy for treating or preventing cancer |
GBGB1805941.0A GB201805941D0 (en) | 2018-04-10 | 2018-04-10 | Combination therapy for treating or preventing cancer |
GBGB1806572.2A GB201806572D0 (en) | 2018-04-23 | 2018-04-23 | Combination therapy for treating or preventing cancer |
GBGB1808632.2A GB201808632D0 (en) | 2018-05-25 | 2018-05-25 | Combination therapy for treating or preventing cancer |
PCT/GB2019/050144 WO2019141999A1 (en) | 2018-01-19 | 2019-01-18 | Combination therapy for treating or preventing cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020007665A true MX2020007665A (es) | 2020-09-14 |
Family
ID=65363308
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020007665A MX2020007665A (es) | 2018-01-19 | 2019-01-18 | Terapia de combinacion para tratar o prevenir el cancer. |
Country Status (14)
Country | Link |
---|---|
US (1) | US20210060094A1 (es) |
EP (1) | EP3740221A1 (es) |
JP (1) | JP2021516661A (es) |
KR (1) | KR20200110343A (es) |
CN (1) | CN111902153A (es) |
AU (1) | AU2019210005A1 (es) |
BR (1) | BR112020014564A2 (es) |
CA (1) | CA3088343A1 (es) |
IL (1) | IL276073A (es) |
MA (1) | MA51621A (es) |
MX (1) | MX2020007665A (es) |
SG (1) | SG11202006874SA (es) |
TW (1) | TW201934138A (es) |
WO (1) | WO2019141999A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210101620A (ko) * | 2020-02-10 | 2021-08-19 | 주식회사 천랩 | 패칼리박테리움 속 균주를 이용한 항암 치료 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0127916D0 (en) | 2001-11-21 | 2002-01-16 | Rowett Res Inst | Method |
US8187803B2 (en) * | 2006-03-31 | 2012-05-29 | Canon Kabushiki Kaisha | Probe, probe set, probe-immobilized carrier, and genetic testing method |
ES2895666T3 (es) | 2006-10-27 | 2022-02-22 | Capsugel Belgium Nv | Cápsulas duras de hidroxipropilmetilcelulosa y proceso de fabricación |
GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
US8906668B2 (en) * | 2012-11-23 | 2014-12-09 | Seres Health, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
TWI664976B (zh) * | 2013-01-02 | 2019-07-11 | 美商迪科生物系統公司 | 使用細菌治療癌症之組成物和方法 |
GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
CA2987129A1 (en) * | 2015-06-01 | 2016-12-08 | The University Of Chicago | Treatment of cancer by manipulation of commensal microflora |
GB201520497D0 (en) * | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
MA41013B1 (fr) * | 2015-11-20 | 2018-07-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
WO2018009528A1 (en) * | 2016-07-05 | 2018-01-11 | Tdw Group | Combination cancer immunotherapies with arginine depletion agents |
MA41708A (fr) * | 2017-05-24 | 2020-04-08 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
-
2019
- 2019-01-18 CN CN201980009092.0A patent/CN111902153A/zh active Pending
- 2019-01-18 MA MA051621A patent/MA51621A/fr unknown
- 2019-01-18 SG SG11202006874SA patent/SG11202006874SA/en unknown
- 2019-01-18 WO PCT/GB2019/050144 patent/WO2019141999A1/en unknown
- 2019-01-18 TW TW108101943A patent/TW201934138A/zh unknown
- 2019-01-18 JP JP2020538811A patent/JP2021516661A/ja active Pending
- 2019-01-18 MX MX2020007665A patent/MX2020007665A/es unknown
- 2019-01-18 CA CA3088343A patent/CA3088343A1/en active Pending
- 2019-01-18 AU AU2019210005A patent/AU2019210005A1/en not_active Abandoned
- 2019-01-18 KR KR1020207021008A patent/KR20200110343A/ko active Search and Examination
- 2019-01-18 EP EP19704381.3A patent/EP3740221A1/en active Pending
- 2019-01-18 BR BR112020014564-5A patent/BR112020014564A2/pt not_active IP Right Cessation
-
2020
- 2020-07-15 IL IL276073A patent/IL276073A/en unknown
- 2020-07-17 US US16/932,048 patent/US20210060094A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP3740221A1 (en) | 2020-11-25 |
MA51621A (fr) | 2020-11-25 |
TW201934138A (zh) | 2019-09-01 |
SG11202006874SA (en) | 2020-08-28 |
IL276073A (en) | 2020-08-31 |
AU2019210005A1 (en) | 2020-08-06 |
CA3088343A1 (en) | 2019-07-25 |
BR112020014564A2 (pt) | 2020-12-08 |
KR20200110343A (ko) | 2020-09-23 |
US20210060094A1 (en) | 2021-03-04 |
WO2019141999A1 (en) | 2019-07-25 |
WO2019141999A8 (en) | 2020-09-17 |
CN111902153A (zh) | 2020-11-06 |
JP2021516661A (ja) | 2021-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021000710A (es) | Composiciones que comprenden cepas bacterianas. | |
PH12020551080A1 (en) | Combination therapy for treating or preventing cancer | |
MX2020003770A (es) | Terapias de combinacion para tratar cancer. | |
MD3600363T2 (ro) | Compoziții cuprinzând tulpini bacteriene | |
EA201991818A1 (ru) | Лечение рака | |
MX2020009736A (es) | Composiciones que comprenden cepas bacterianas. | |
MX2021003903A (es) | Terapia combinada para el melanoma. | |
MX2020008195A (es) | Compuestos para el tratamiento del dolor. | |
MX2017016114A (es) | Metodos para tratar o prevenir una proteopatia. | |
MX2022007955A (es) | Regimenes de dosificacion de erdafitinib. | |
PH12021550102A1 (en) | Cardiosafe antidiabetic therapy | |
MD3638271T2 (ro) | Compoziții cuprizând tulpini bacteriene | |
WO2018183692A8 (en) | VECTORS AND COMPOSITIONS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | |
MX2021009670A (es) | Tratamiento para el cancer. | |
MX2020007664A (es) | Terapia de combinacion para tratar o prevenir el cancer. | |
MX2020007681A (es) | Terapia de combinacion para tratar o prevenir el cancer. | |
MX2020007665A (es) | Terapia de combinacion para tratar o prevenir el cancer. | |
MX2020012964A (es) | Metodos para el tratamiento de cancer de vejiga. | |
MX2021013908A (es) | Tratamiento para el cáncer. | |
EA202091635A1 (ru) | Комбинированная терапия для лечения или профилактики рака | |
EA202091730A1 (ru) | Комбинированная терапия для лечения или профилактики рака | |
EA202091636A1 (ru) | Комбинированная терапия для лечения или профилактики рака | |
MX2019009199A (es) | Composiciones y métodos para modular ppp2r1a. | |
GB201808636D0 (en) | Combination therapy for treating or preventing cancer | |
MX2021013776A (es) | Composiciones que comprenden cepas bacterianas. |